Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020 16:05 ET
|
Alector, Inc.
Global Phase 3 INFRONT-3 trial evaluating AL001 for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) currently enrolling participantsOn track to initiate Phase 2 study...
Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
November 02, 2020 07:44 ET
|
Alector, Inc.
Independent arbitrator finds in favor of Alector in confidential arbitration proceedingsDr. Abeliovich remains bound by contractual obligations related to the confidentiality of the company’s...
Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
October 22, 2020 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of...
Alector to Participate at Virtual Investor Conferences in September
September 03, 2020 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of...
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 11, 2020 16:05 ET
|
Alector, Inc.
Pivotal Phase 3 trial of AL001 initiated for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)Promising preliminary data from AL001 Phase 1b and Phase 2 open-label...
Alector to Present at the BTIG Virtual Biotechnology Conference 2020
August 04, 2020 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney,...
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia
July 28, 2020 18:00 ET
|
Alector, Inc.
AL001 was generally safe and well-tolerated in Phase 1b study and after continuous dosing in 15 asymptomatic and symptomatic FTD-GRN participants in Phase 2 studyTreatment with AL001 in Phase 2 study...
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
July 24, 2020 08:30 ET
|
Alector, Inc.
Trial will enroll up to 180 symptomatic and pre-symptomatic participants with FTD-GRN gene mutation at multiple sites in the U.S., Europe and Australia There are currently no FDA-approved treatments...
Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference
July 21, 2020 17:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will...
Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine
June 25, 2020 09:00 ET
|
Alector, Inc.
Antibody-mediated engagement of TREM2 expanded unique subpopulations of metabolically active and proliferating microglia in a human TREM2 expressing mouse model of Alzheimer’s disease Chronic...